You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropafenone
Accession NumberDB01182  (APRD00261)
TypeSmall Molecule
GroupsApproved
Description

An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanoneNot AvailableNot Available
2-(2'-Hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenoneNot AvailableNot Available
PropafenonaSpanishINN
PropafenonumLatinINN
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Rythmoltablet, film coated150 mgoralGlaxo Smith Kline Llc2010-01-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rythmoltablet, film coated225 mgoralGlaxo Smith Kline Llc2010-01-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rythmol SRcapsule, extended release225 mgoralGlaxo Smith Kline Llc2011-03-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rythmol SRcapsule, extended release325 mgoralGlaxo Smith Kline Llc2011-03-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rythmol SRcapsule, extended release425 mgoralGlaxo Smith Kline Llc2011-03-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Rythmoltablet150 mgoralBgp Pharma UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Rythmoltablet300 mgoralBgp Pharma UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Propafenone Hydrochloridetablet, film coated150 mgoralQualitest Pharmaceuticals2002-10-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated225 mgoralQualitest Pharmaceuticals2002-10-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated300 mgoralQualitest Pharmaceuticals2002-10-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated150 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-10-17Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenonecapsule, extended release325 mgoralRebel Distributors Corp2011-01-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridecapsule, extended release225 mgoralPar Pharmaceutical, Inc.2011-01-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridecapsule, extended release325 mgoralPar Pharmaceutical, Inc.2011-01-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridecapsule, extended release425 mgoralPar Pharmaceutical, Inc.2011-01-03Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated150 mgoralMylan Institutional Inc.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated150 mgoralMutual Pharmaceutical Co., Inc.2001-11-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated225 mgoralMutual Pharmaceutical Co., Inc.2001-11-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated300 mgoralMutual Pharmaceutical Co., Inc.2001-11-29Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated150 mgoralPhysicians Total Care, Inc.2005-05-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated225 mgoralPhysicians Total Care, Inc.2008-10-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridetablet, film coated150 mgoralCardinal Health2011-05-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenone Hydrochloridecapsule, extended release225 mgoralAmerican Health Packaging2014-10-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Propafenonetablet150 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Propafenonetablet300 mgoralSanis Health IncNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Over the Counter ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Propafenone hydrochloride
34183-22-7
Thumb
  • InChI Key: XWIHRGFIPXWGEF-UHFFFAOYNA-N
  • Monoisotopic Mass: 377.175771474
  • Average Mass: 377.905
DBSALT000148
Categories
CAS number54063-53-5
WeightAverage: 341.444
Monoisotopic: 341.199093735
Chemical FormulaC21H27NO3
InChI KeyJWHAUXFOSRPERK-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
IUPAC Name
1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
SMILES
CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as chalcones and dihydrochalcones. These are organic compounds containing 1,3-Diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar,or its derivatives formed by substitution.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassLinear 1,3-diarylpropanoids
Sub ClassChalcones and dihydrochalcones
Direct ParentChalcones and dihydrochalcones
Alternative Parents
Substituents
  • Chalcone or dihydrochalcone
  • Butyrophenone
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Secondary alcohol
  • Ketone
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
PharmacodynamicsPropafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. It is used in the treatment of atrial and ventricular arrhythmias. It works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitablity of the cells. Propafenone has local anesthetic activity approximately equal to procaine.
Mechanism of actionThe electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.
AbsorptionNearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).
Volume of distribution
  • 252 L
Protein binding97%
Metabolism

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations.

SubstrateEnzymesProduct
Propafenone
N-desalkylpropafenoneDetails
Propafenone
5-hydroxypropafenoneDetails
Propafenone
Not Available
N-depropylpropafenoneDetails
Route of eliminationApproximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.
Half life2-10 hours
ClearanceNot Available
ToxicitySymptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier-0.958
Caco-2 permeable-0.5433
P-glycoprotein substrateSubstrate0.8548
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.874
Renal organic cation transporterNon-inhibitor0.7204
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5499
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 substrateNon-inhibitor0.9071
CYP450 2D6 substrateInhibitor0.8932
CYP450 2C19 substrateNon-inhibitor0.9026
CYP450 3A4 substrateInhibitor0.7066
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8931
Ames testNon AMES toxic0.8446
CarcinogenicityNon-carcinogens0.8879
BiodegradationNot ready biodegradable0.803
Rat acute toxicity2.3795 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5383
hERG inhibition (predictor II)Inhibitor0.8915
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseoral225 mg
Capsule, extended releaseoral325 mg
Capsule, extended releaseoral425 mg
Tabletoral150 mg
Tabletoral300 mg
Tablet, film coatedoral150 mg
Tablet, film coatedoral225 mg
Tablet, film coatedoral300 mg
Prices
Unit descriptionCostUnit
Rythmol SR 325 mg 12 Hour Capsule8.9USD capsule
Rythmol SR 425 mg 12 Hour Capsule8.9USD capsule
Rythmol sr 325 mg capsule8.56USD capsule
Rythmol sr 425 mg capsule8.56USD capsule
Rythmol SR 225 mg 12 Hour Capsule7.02USD capsule
Rythmol sr 225 mg capsule6.75USD capsule
Rythmol 225 mg tablet6.2USD tablet
Rythmol 300 mg tablet5.05USD tablet
Rythmol 150 mg tablet3.95USD tablet
Propafenone hcl 300 mg tablet3.03USD tablet
Propafenone hcl 225 mg tablet2.38USD tablet
Rythmol 300 mg Tablet2.09USD tablet
Propafenone hcl 150 mg tablet1.64USD tablet
Rythmol 150 mg Tablet1.18USD tablet
Apo-Propafenone 300 mg Tablet0.79USD tablet
Pms-Propafenone 300 mg Tablet0.79USD tablet
Apo-Propafenone 150 mg Tablet0.45USD tablet
Pms-Propafenone 150 mg Tablet0.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
CountryPatent NumberApprovedExpires (estimated)
United States56815881994-10-282014-10-28
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00758 mg/mLALOGPS
logP3.1ALOGPS
logP3.54ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity100.21 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Helmut Lietz, “Preparation of propafenone.” U.S. Patent US4474986, issued May, 1974.

US4474986
General ReferenceNot Available
External Links
ATC CodesC01BC03
AHFS Codes
  • 24:04.04.12
PDB EntriesNot Available
FDA labelDownload (91.1 KB)
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
AbirateroneMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
AcebutololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
AcenocoumarolMay increase the serum concentration of Vitamin K Antagonists.
AminophyllineMay increase the serum concentration of Theophylline Derivatives.
AmiodaroneAmiodarone may enhance the adverse/toxic effect of Propafenone. Specifically, the combination may result in altered cardiac conduction and repolarization. Amiodarone may increase the serum concentration of Propafenone.
AmobarbitalBarbiturates may decrease the serum concentration of Propafenone.
AprepitantCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
AripiprazoleCYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.
AtazanavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
BetaxololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
BicalutamideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
BiotinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
BisoprololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
BoceprevirMay increase the serum concentration of Propafenone.
BretyliumMay enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
BupropionCYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.
ButabarbitalBarbiturates may decrease the serum concentration of Propafenone.
ButalbitalBarbiturates may decrease the serum concentration of Propafenone.
ButethalMay decrease the serum concentration of Propafenone.
CarvedilolMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
CelecoxibMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
CimetidineCimetidine may increase the serum concentration of Propafenone.
CinacalcetCYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.
ClobazamMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
ClomipramineMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
ClotrimazoleCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
CocaineCYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.
ConivaptanCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
DarifenacinMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
DarunavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
DelavirdineCYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.
DesipramineMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
DigoxinMay increase the serum concentration of Cardiac Glycosides.
DiltiazemCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
DisopyramideMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).
DofetilideMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
DronedaroneMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
DuloxetineMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
EsmololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
EtravirineMay decrease the serum concentration of Propafenone.
FluoxetineMay enhance the QTc-prolonging effect of FLUoxetine. FLUoxetine may increase the serum concentration of Propafenone.
FluvoxamineFluvoxaMINE may increase the serum concentration of Propafenone.
FosamprenavirMay increase the serum concentration of Propafenone.
FosaprepitantCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
HeptabarbitalMay decrease the serum concentration of Propafenone.
HexobarbitalMay decrease the serum concentration of Propafenone.
IbutilideMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
ImipramineMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
IndinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
IsavuconazoniumCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
IsoniazidMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
ItraconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
LabetalolMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
LacosamideBradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
LomitapideCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
LopinavirRitonavir may increase the serum concentration of Propafenone.
LorcaserinMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
MethohexitalBarbiturates may decrease the serum concentration of Propafenone.
MethotrimeprazineCYP2D6 Inhibitors (Strong) may increase the serum concentration of Propafenone.
MetoprololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
MifepristoneMay enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.
MirabegronMay increase the serum concentration of Propafenone.
NebivololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
NefazodoneCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
NelfinavirCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
NorfloxacinCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
OrlistatOrlistat may decrease the serum concentration of Propafenone.
ParoxetinePARoxetine may increase the serum concentration of Propafenone.
PenbutololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
PentobarbitalBarbiturates may decrease the serum concentration of Propafenone.
PhenobarbitalBarbiturates may decrease the serum concentration of Propafenone.
PindololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
PosaconazoleCYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.
PrimidoneMay decrease the serum concentration of Propafenone.
ProcainamideMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).
ProcaineMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class Ia).
PropranololMay increase the serum concentration of Propranolol.
QuinidineQuiNIDine may enhance the QTc-prolonging effect of Propafenone. QuiNIDine may increase the serum concentration of Propafenone.
RifampicinRifamycin Derivatives may decrease the serum concentration of Propafenone.
RifapentineRifamycin Derivatives may decrease the serum concentration of Propafenone.
RitonavirRitonavir may increase the serum concentration of Propafenone.
RuxolitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
SaquinavirMay enhance the arrhythmogenic effect of Propafenone. Saquinavir may increase the serum concentration of Propafenone.
SecobarbitalBarbiturates may decrease the serum concentration of Propafenone.
SertralineSertraline may enhance the QTc-prolonging effect of Propafenone. Sertraline may increase the serum concentration of Propafenone.
SotalolMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
TelaprevirMay enhance the adverse/toxic effect of Propafenone.
TetracyclineCYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.
TheophyllineMay increase the serum concentration of Theophylline Derivatives.
TiclopidineMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
TimololMay increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.
TipranavirTipranavir may increase the serum concentration of Propafenone.
TofacitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
TranylcypromineMay increase the serum concentration of CYP2D6 Inhibitors (Moderate).
VenlafaxineMay increase the serum concentration of Venlafaxine.
Food Interactions
  • Always take at the same time in regard to meals.
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.

Targets

1. Sodium channel protein type 5 subunit alpha

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Sodium channel protein type 5 subunit alpha Q14524 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

2. Potassium voltage-gated channel subfamily H member 2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Potassium voltage-gated channel subfamily H member 2 Q12809 Details

References:

  1. Mergenthaler J, Haverkamp W, Huttenhofer A, Skryabin BV, Musshoff U, Borggrefe M, Speckmann EJ, Breithardt G, Madeja M: Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):472-80. Pubmed
  2. Arias C, Gonzalez T, Moreno I, Caballero R, Delpon E, Tamargo J, Valenzuela C: Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res. 2003 Mar;57(3):660-9. Pubmed
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

Enzymes

1. Cytochrome P450 2D6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2D6 P10635 Details

References:

  1. Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine (2007). Accessed May 28, 2010.
  2. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. Pubmed
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

2. Cytochrome P450 3A4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Cytochrome P450 3A4 P08684 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

3. Cytochrome P450 1A2

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Cytochrome P450 1A2 P05177 Details

References:

  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. Pubmed
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

4. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

5. Cytochrome P450 2C8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C8 P10632 Details

References:

  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. Epub 2009 Nov 24. Pubmed

Transporters

1. Multidrug resistance protein 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Multidrug resistance protein 1 P08183 Details

References:

  1. Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P: Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol. 1999 Nov 1;58(9):1447-56. Pubmed
  2. Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF: Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2005 Mar;371(3):195-201. Epub 2005 Apr 15. Pubmed
  3. Singh P, Paul K: Studies of interactions between uracil-based hybrid molecules and P-glycoprotein—search for multidrug resistance modulators. Bioorg Med Chem. 2006 Nov 1;14(21):7183-6. Epub 2006 Jul 14. Pubmed
  4. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther. 1997 Oct;283(1):39-45. Pubmed
  5. Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper KJ, Ecker G: A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim). 1998 Jul-Aug;331(7-8):233-40. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 16, 2013 17:13